<DOC>
	<DOCNO>NCT01844804</DOCNO>
	<brief_summary>In study , healthy volunteer receive single intravenous dose either PF-06438179 infliximab ( United States ) infliximab ( European Union ) . During course study , pharmacokinetics assess sampling level drug blood , compare level among different administration arm PF-06438179 license infliximab product . Safety , tolerability , immunologic response also evaluate throughout .</brief_summary>
	<brief_title>A Pharmacokinetics Study Comparing PF-06438179 Infliximab Healthy Volunteers ( REFLECTIONS B537-01 )</brief_title>
	<detailed_description />
	<mesh_term>Infliximab</mesh_term>
	<criteria>Healthy female subject nonchildbearing potential healthy male subject ( healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12lead ECG clinical laboratory test ) . Body Mass Index ( BMI ) 17.5 32.0 kg/m2 ; total body weight &gt; 50kg ( 110 lb ) . Evidence history clinically significant infectious , hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , autoimmune , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Previous exposure monoclonal antibody , current use biologics . History hypersensitivity reaction inactive component study drug murine proteins anaphylactic reaction therapeutic drug . History tuberculosis ( TB ) positive latent TB test Screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Biosimilarity</keyword>
	<keyword>Similarity</keyword>
	<keyword>PK</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Infliximab</keyword>
	<keyword>Healthy Volunteers</keyword>
	<keyword>Single-dose</keyword>
	<keyword>Immunology</keyword>
</DOC>